DataM Intelligence Projects In-Silico Clinical Trials Market to Reach $6.39 Billion by 2033

The in-silico clinical trials market is projected to reach USD 6.39 billion by 2033, up from USD 3.95 billion in 2024, expanding at a compound annual growth rate of 5.5% between 2025 and 2033, announced in a press release by DataM Intelligence.

In-silico trials use computational modeling, virtual patient simulations, and AI-driven predictive systems to digitally test drug candidates, medical devices, and treatment protocols. These digital simulations complement laboratory and clinical studies by improving prediction accuracy and reducing experimental workloads.

The report highlights that pharmaceutical companies, medical device manufacturers, contract research organizations, and academic institutions are increasingly adopting in-silico trial platforms to modernize clinical development. The approach helps address challenges such as high development costs, regulatory delays, and patient recruitment difficulties, ultimately shortening the time to market for new therapies.